Abstract Indomethacin (INDO) has the potential to be a useful tool to explore the influence of cerebral blood flow and its responses to CO 2 on ventilatory control. However, the effect of INDO on the cerebrovascular and ventilatory response to hypoxia remains unclear; therefore, we examined the effect of INDO on ventilatory and cerebrovascular sensitivity to hypoxia and hypercapnia. We measured endtidal gases, ventilation ð _ V E Þ; and middle cerebral artery velocity (MCAv) before and 90 min following INDO (100 mg) in 12 healthy participants at rest and during hyperoxic hypercapnia and isocapnic hypoxia. Following INDO, resting _ V E and end-tidal gases were unaltered (P [ 0.05), whilst MCAv was lowered by 25 ± 19% (P \ 0.001). INDO ingestion reduced MCAv-CO 2 reactivity by 46 ± 29% (2.9 ± 0.9 vs. 1.7 ± 0.9 cm s -1 mmHg -1 ; P \ 0.001) and enhanced the _ V E -CO 2 sensitivity by 0.5 ± 0.5 L min -1 mmHg -1 (1.9 ± 1.5 vs. 2.3 ± 1.6 L min -1 mmHg -1 ; P \ 0.05). No changes were observed in either the MCAv or _ V E responsiveness to isocapnic hypoxia following INDO ingestion (P [ 0.05). These findings indicate that INDO does not alter cerebrovascular and ventilatory responsiveness to hypoxia, indicating a preserved peripheral chemoreflex in response to this pharmacological agent.
Introduction
The net [H ? ] in the environment of central chemoreceptors is dependent on the rate of CO 2 production and the rate of CO 2 washout in the brain. The former is determined by cerebral metabolism, whilst the latter is regulated by the cerebral blood flow (CBF) response to changes in the partial pressure of arterial CO 2 (P a CO 2 ) in the braintermed cerebrovascular CO 2 reactivity. For example, reduced resting CBF and blunted cerebrovascular CO 2 reactivity have been shown to increase the jugular venous PCO 2 (Chapman et al. 1979a) , whilst an increase in CBF lowers brain tissue PCO 2 (Fencl 1986 ). Accordingly, it has been proposed that CBF and cerebrovascular CO 2 reactivity may help regulate central (i.e. brain) pH, and thus affects the most important input to respiratory drive (cen Chapman et al. (1979a) previously reported that, in unanaesthetised goats, a 30% reduction in CBF and cerebrovascular CO 2 reactivity (via carotid clamping) elevates jugular venous PCO 2 and augments the ventilatory response to hyperoxic rebreathing, but not to transient hypoxia. Since hyperoxia is known to silence the peripheral chemoreceptor activity (Cunningham et al. 1963; Gardner 1980; Mohan and Duffin 1997) , Chapman et al. (1979a) proposed that a blunted cerebrovascular CO 2 reactivity, by attenuating the washout of H ? from the brain, selectively enhances the central chemoreflex without altering the peripheral chemoreflex. In the same study, they also found that further reductions in CBF (50%) and near abolishment of cerebrovascular CO 2 reactivity depresses both the central and peripheral chemoreflexes, presumably due to the hypoxic depression of respiratory neurons associated with severe cerebral ischaemia (Chapman et al. 1979b ). In addition, Nishimura et al. (1987) provided evidence that the cerebrovascular responsiveness to hypoxia modulates the ventilatory responsiveness to hypoxia via H ? washout from the brain, thereby attenuating the central drive, at least during moderate hypoxic exposure. Taken together, these findings support the role of CBF and its responses to CO 2 and O 2 in the control of breathing.
Indomethacin (INDO) is a potent reversible cyclooxygenase inhibitor, which has been shown to impair the cerebral vessels' ability to dilate in response to potent vasodilatory stimulus such as hypercapnia and iloprost (a prostacyclin receptor agonist) (Parfenova et al. 1994; Parfenova et al. 1995b) . Accordingly, the authors concluded that INDO lowers CBF and cerebrovascular CO 2 reactivity by selective inhibition of prostaglandin H synthase and prostacyclin receptor-mediated responses (Parfenova et al. 1995b) . Moreover, numerous studies have found that INDO lowers CBF and attenuates the cerebrovascular reactivity to CO 2 (Bruhn et al. 2001; Eriksson et al. 1983; Ivancev et al. 2009; Kastrup et al. 1999; Markus et al. 1994; St Lawrence et al. 2002; Wennmalm et al. 1983 ) without concomitant changes in cerebral metabolic rate (Hohimer et al. 1985; Kraaier et al. 1992) or plasma catecholamines (Green et al. 1987; Staessen et al. 1984; Wennmalm et al. 1984) . Recently, it had been demonstrated that INDO (100 mg) enhances the central chemoreflex Xie et al. 2006) , increases the propensity for apnoea during sleep in healthy humans (Xie et al. 2009 ) and exacerbates the severity of obstructive sleep apnoea . These changes in ventilatory control were attributed to the INDO-induced reduction in cerebrovascular CO 2 reactivity and associated reduction in H ? washout, resulting in an increase in central chemoreceptor activation (Hohimer et al. 1985) . Despite the numerous studies on the central chemoreflex, however, the effect of INDO on peripheral chemoreflex in humans is yet to be examined.
Animal studies have reported an enhanced carotid body chemosensitivity to hypoxia and hypercapnia with INDO, whilst no changes were observed under normoxic and eucapnic conditions (Gomez-Nino et al. 1992 . In contrast, other studies have found that, since bilateral carotid section failed to abolish INDO-induced increases in respiratory movement or _ V E ;, the effect of INDO on _ V E is unlikely to be mediated by the carotid bodies (Jansen et al. 1984; McQueen and Belmonte 1974) . In healthy resting humans, Xie et al. (2006) found that oral INDO caused a 37% reduction in cerebrovascular CO 2 reactivity and a 40-60% increase in the _ V E responsiveness to steady-state hyperoxic hypercapnia and normoxic hypercapnia. Since no differences were observed between the hyperoxic and normoxic conditions, it was proposed that the observed increase in ventilatory sensitivity to CO 2 following INDO was primarily due to an augmented central chemoreceptor activation via reduced H ? washout in the brainstem, rather than any concurrent changes in peripheral chemoreflex (Xie et al. 2006) . However, since the nature of the interactions between central and peripheral chemoreceptors is yet unclear (Blain et al. 2009; Dahan et al. 2008; Day and Wilson 2009) , the findings by Xie et al. (2006) should be interpreted with caution. As such, no studies have yet examined the effect of INDO on the ventilatory responsiveness to hypoxia per se. Likewise, previous animal studies have demonstrated that INDO blunts the CBF response to hypoxia (cerebrovascular O 2 reactivity) in a dose-dependent manner (Coyle et al. 1993 (Coyle et al. , 1995 . However, the effect of INDO on the cerebrovascular reactivity to hypoxia has not been previously examined in humans. Since cerebrovascular hypoxic reactivity plays an important role in modulating hypoxic ventilatory response (Nishimura et al. 1987) , INDO-induced changes in the cerebrovascular O 2 reactivity may account, in part, for any potential alterations in the peripheral chemoreflex.
The purpose of this study was to examine the effect of INDO on the CBF and _ V E response to hypoxia in humans. We examined the hypothesis that INDO-induced reduction in cerebrovascular CO 2 reactivity would augment _ V E responsiveness to CO 2 without any concurrent alterations in the cerebrovascular and ventilatory responsiveness to hypoxia.
Methods

Participants
Twelve adults (8 male and 4 female) with a mean age of 30 ± 10 years (mean ± SD), and body mass index of 23 ± 2 kg m -2 participated in this study. Participants were non-smokers, had no previous history of cardiovascular, cerebrovascular or respiratory diseases and were not taking any medications. All participants were informed regarding the purposes and procedures of this study, and informed consent was given prior to participation. The study was approved by the Lower South Regional Ethics Committee of Otago and conformed to the standards set by the Declaration of Helsinki.
Experimental design
The participants were required to visit the laboratory on two occasions. After a full familiarisation with the experimental procedures outlined below (visit one), participants underwent one experimental trial (INDO). To account for the time course effect, 7 of the 12 participant also underwent a placebo trial (randomised order) separated by at least 7 days. Both the INDO (100 mg) and placebo trials were administered in identical-looking capsules and ingested with 20 mL of antacid (Maalox). Before each experimental session, participants were informed to abstain from exercise and alcohol for 24 h, caffeine for 12 h and a heavy meal for 4 h prior. Experiments were conducted at the same time of day for each participant to reduce the known influence of circadian rhythm on the key cardiorespiratory and cerebrovascular variables (Ainslie and Duffin 2009) . All experiments were performed with participants semirecumbent and with temperate controlled at 22°C. Following 10-15 min of quiet rest, each experimental testing session comprised: (a) instrumentation; (b) hyperoxic hypercapnia and isocapnic hypoxia; (c) INDO/placebo administration; (d) 90-min rest, and (e) repeat testing of (a) and (b). The order of the hyperoxic hypercapnia and isocapnic hypoxia was randomised and full recovery (5 min) was permitted between each trial to restore end-tidal gases to baseline resting values.
Hyperoxic hypercapnia
The participants breathed through a leak-free respiratory mask (Hans-Rudolph 8980, Kansas City, MO) attached to a one-way non-rebreathing valve (Hans-Rudolph 2700). The inspiratory line contained a Y-valve, which allowed switching from room air to a 200-L Douglas bag containing 7% CO 2 and 93% O 2 . The steady-state test began with 2 min of baseline room air breathing, before switching onto the Douglas bag for 4 min.
Isocapnic hypoxia
Participants wore a nose clip and breathed through a mouthpiece connected to a Y-valve allowing switching from room air to a circuit consisting of a 6-L rebreathing bag and a soda lime reservoir. Isocapnic hypoxia began with 2-min baseline room air breathing, before participants switched to the rebreathing circuit at the end of inspiration. Isocapnic hypoxia was terminated when: (1) the participant's peripheral O 2 saturation (S p O 2 ) reached 80%; (2) the participant's partial pressure of end-tidal O 2 (P ET O 2 ) reached 45 mmHg; (3) the participant's _ V E exceeded 100 L min -1 ; or (4) the participant reached the end of his tolerance.
Measurements
Respiratory variables
Pulmonary _ V E and its components, tidal volume (V T ) and breathing frequency (f), were measured using a heated pneumotachograph (Hans-Rudolph HR800) and expressed in units adjusted to BTPS. The fractional changes in inspired and expired O 2 and CO 2 were used to calculate partial pressure of end-tidal O 2 and CO 2 (P ET CO 2 ) with fast responding gas analysers (AEI Technologies, Pittsburgh, PA). The pneumotachograph was calibrated using a 3-L syringe (Hans-Rudolph 2700, Kansas City, MO) and the gas analysers were calibrated using known concentrations of O 2 and CO 2 prior to each testing session.
Cerebrovascular and cardiovascular variables
Middle cerebral artery velocity (MCAv, an index of CBF) was measured in the right middle cerebral artery using a 2-MHz pulsed Doppler ultrasound system (DWL Doppler, Sterling, VA). The Doppler ultrasound probe was positioned over the right temporal window and held in place with an adjustable plastic headband. The signals were obtained using search techniques described elsewhere (Aaslid et al. 1982) . Frontal cortical cerebral oxygenation was measured in seven participants using near-infrared spectroscopy (NIRS) (NIRO-200; Hamamatsu Photonics; Hamamatsu, Japan). A probe holder containing an emission probe and detection probe was attached at the right side of the forehead with a distance of 5 cm between the probes. The methodology of this system has been described previously (Al-Rawi et al. 2001; Nollert et al. 1995) . Heart rate (HR) was determined using a three-lead ECG. Beatto-beat mean arterial blood pressure (MAP) was monitored using finger photoplethysmography (Finometer, TPD Biomedical Instrumentation). To ensure accurate measurements of MAP, right arm manual blood pressure measurements by auscultation were also made periodically to check and validate the automated recordings. Cerebrovascular conductance index (CVCi) was estimated by dividing mean MCAv by MAP within each breath cycle to reveal intrinsic vascular responses to CO 2 (Claassen et al. 2007 ). Peripheral O 2 saturation (S p O 2 ) was obtained using a finger pulse oximeter.
Data analysis
Hyperoxic hypercapnia _ V E ; MCAv and CVCi responsiveness to CO 2 was estimated from the slope of the mean value of each dependant variable in the final minute of baseline and steady-state hyperoxic hypercapnic breathing. Steady-state hypocapnic cerebrovascular reactivity was estimated from the slope of the mean MCAv in the final minute of baseline and voluntary hyperventilation prior to the rebreathing. It should be acknowledged that the steady-state determination of ventilatory CO 2 sensitivity is restricted to the number of data points used in the analysis (Mohan et al. 1999; Pandit et al. 2007 ). However, the steady-state _ V E -CO 2 sensitivities (control and INDO) observed in the present study ( Fig. 1) were comparable to those reported by Xie et al. (2006) who used four steady-state data points (baseline, 2, 4 and 6% CO 2 ), thereby supporting the use of two data points in estimating steady-state ventilatory CO 2 sensitivity in the present study.
Isocapnic hypoxia
To express the _ V E and MCAv changes as a linear function of the hypoxic stimulus during isocapnic hypoxia, P ET O 2 was converted to a calculated arterial O 2 saturation (S c O 2 ) using the equation (Severinghaus 1979 ):
where S c O 2 is a percentage and P ET O 2 is in mmHg. Changes in _ V E and MCAv were then subsequently plotted against S c O 2 using linear regression to obtain the respiratory and cerebrovascular responsiveness to hypoxia.
Statistical analysis
To assess the effect of INDO on resting variables, ventilatory and cerebrovascular changes during hyperoxic hypercapnia and isocapnic hypoxia, we used paired t test with a-level of P \ 0.05 (SPSS version 17.0, SPSS, Chicago, IL). Likewise, to assess the effect of placebo on resting variables, ventilatory and cerebrovascular changes during hyperoxic hypercapnia and isocapnic hypoxia, we used paired t test with a-level of P \ 0.05.
Results
All 12 participants completed the placebo and INDO trial with the hyperoxic hypercapnia and isocapnic hypoxia.
Baseline
Indomethacin ingestion reduced both MCAv and CVCi by 25 ± 19 and 31 ± 22%, respectively, from baseline (P \ 0.001; Table 1), whilst no changes were observed following placebo ingestion (P [ 0.05; Table 1 ). In contrast, placebo ingestion increased cerebral oxygenation by 4.7 ± 4.4% (P \ 0.05; Cerebrovascular and ventilatory responsiveness to hypercapnia and hypoxia During the hyperoxic hypercapnia, INDO lowered the MCAv-CO 2 reactivity by 46 ± 29% (2.9 ± 0.9 versus 1.7 ± 0.9 cm s -1 mmHg -1 ; P \ 0.001; Fig. 1 ) and increased the _ V E -CO 2 sensitivity by 0.5 ± 0.5 L min -1 mmHg -1 (1.9 ± 1.5 vs. 2.3 ± 1.6 L min -1 mmHg -1 ; P \ 0.01), whilst no changes were observed with placebo (P [ 0.05). No differences were observed in either the MCAv-S c O 2 reactivity or _ V E -S c O 2 sensitivity during isocapnic hypoxia following either placebo or INDO ingestion (P [ 0.05; Fig. 2 ).
Discussion
The major findings from the present study are that INDO selectively blunts the cerebrovascular CO 2 reactivity and enhances the ventilatory CO 2 sensitivity without affecting either the cerebrovascular or the ventilatory responsiveness to hypoxia.
Methodological considerations
Indomethacin
Indomethacin was used in this study as a pharmacological means to reduce cerebrovascular CO 2 reactivity in healthy resting humans without concomitant changes in cerebral metabolic rate (Hohimer et al. 1985; Kraaier et al. 1992) or plasma catecholamine concentrations (Green et al. 1987; Staessen et al. 1984; Wennmalm et al. 1984) . Studies have shown that the peak effect of INDO (100 mg) on reducing MCAv occurs at *90 min and persists for [4 h following ingestion (Markus et al. 1994; Xie et al. 2006) . It is therefore reasonable to assume that, in the present study, both MCAv and the cerebrovascular CO 2 reactivity would be significantly attenuated for the duration of the experimental trials following INDO ingestion (i.e. data were collected between *90 and 150 min following ingestion).
Indomethacin is one of many commonly used antiinflammatory non-steroids (e.g. aspirin, ibuprofen, naproxen, sulindac), which inhibit prostaglandin synthesis by reversible inhibition of fatty acid cyclooxygenase, an important catalyst in the transformation of arachidonic acid to prostaglandins. Parfenova et al. (1994 Parfenova et al. ( , 1995b found, in newborn pigs, the normal increases in pial arteriolar diameter and cortical cerebrospinal cAMP with either iloprost (a prostacyclin receptor agonist) or hypercapnia were abolished or severely attenuated following INDO; also, the cerebrovascular response to isoproterenol (b-adrenoreceptor agonist) was unaffected. Since shortterm exposure to hypercapnia elevates cAMP in the vascular smooth muscles both directly and indirectly via prostaglandin-mediated endothelial pathways, resulting in cerebrovascular dilation (Hsu et al. 1993; Parfenova and Leffler 1996; Parfenova et al. 1994) , such findings indicate that INDO attenuates normal cerebrovascular CO 2 reactivity via selective inhibition of both prostaglandin H synthase and prostacyclin receptor-mediated responses (Parfenova et al. 1995a, b; Wagerle and Degiulio 1994) . In support of this, Pickard et al. (1980) found the INDOinduced reduction in cerebrovascular CO 2 reactivity was reversed with intracarotid prostacyclin infusion in baboons. In addition, INDO has been shown to partially A B Fig. 1 The cerebrovascular and ventilatory responsiveness to CO 2 during hyperoxic hypercapnia before and following INDO. a Individual slopes; b group data (mean ± SD). Cerebrovascular CO 2 reactivity (MCAv-CO 2 reactivity); ventilatory CO 2 sensitivity ( _ V E -CO 2 sensitivity). Indomethacin ingestion lowered the MCAv-CO 2 slope and enhanced _ V E -CO 2 sensitivity. **Different from control (P \ 0.01); ***different from control (P \ 0.001) inhibit lipopolysaccharide-induced dilation in the cerebrovasculature (Brian et al. 1998) .
Interestingly, studies have only reported reductions in resting CBF and cerebrovascular responsiveness to CO 2 following oral ingestion of INDO, but not aspirin, sulindac, naproxen or ibuprofen Markus et al. 1994; Parfenova et al. 1995b; Wagerle and Degiulio 1994) . This lack of change in basal CBF and cerebrovascular CO 2 reactivity has led to speculations that these other non-steroidal anti-inflammatory drugs may not cross the bloodbrain barrier sufficiently to alter cerebrovascular function or are less effective in the inhibition of prostanoid-induced cAMP formation (Parfenova et al. 1995b) . In support of this, both aspirin and ibuprofen failed to inhibit the pial arteriolar dilation response to hypercapnia despite being effective in inhibiting prostanoids synthesis (Parfenova et al. 1995b; Wagerle and Degiulio 1994) . Moreover, Parfenova et al. (1995b) found, in contrast to INDO (5 mg kg -1 i.v.), aspirin (50 mg kg -1 i.v.) failed to attenuate the prostacyclin receptor-mediated increase in cAMP formation by the microvascular smooth muscle and endothelial cells. The authors speculated that the inhibition of prostanoids production is necessary, but not sufficient, to block the prostanoids-induced cerebrovascular response to hypercapnia. Instead, inhibition of both cortical prostanoids synthase and prostacyclin receptor activation may be needed to blunt the cerebrovascular CO 2 reactivity. Alternatively, it is possible that INDO may alter cerebrovascular function via non-prostaglandin pathways, such as inhibition of histamine release (Konig et al. 1987) , calcium channel blockade (Northover 1977) , potentiation of lipoxygenase pathway (Docherty and Wilson 1987) , modification of extracellular pH (Wang et al. 1993 ), INDO's scavenging effect on inhibition of superoxide generation (Pourcyrous et al. 1993) , or via increases in endothelin-1 (Therkelsen et al. 1994 ). Most noteworthy is the finding by Wang et al. (1993) , which showed that INDO abolished the acetazolamide-induced increase in CBF. Since acetazolamide is known to increase cerebral acidosis via a carbonic anhydrase inhibition and associated increase in CO 2 retention, the authors conclude that INDO acts to lower the cerebrovascular CO 2 reactivity by a non-prostaglandin-mediated mechanism that directly interferes with the regulation of CBF and cerebrovascular tone mediated by an increase in extracellular pH. However, Hohimer et al. (1985) found INDO-induced reduction in CBF increased the sagittal vein [H ? ]. Therefore, it seems unlikely that INDO directly alters cerebral pH. Moreover, an increase in cerebral pH would attenuate, rather than augment, the ventilatory response to hyperoxic hypercapnia.
Assessment of CBF
In this study, transcranial Doppler ultrasound was used to measure the MCAv as an index of global CBF responsiveness to CO 2 . Numerous studies have provided evidence, which support the validity of MCAv as an index of regional CBF (Bishop et al. 1986; Nuttall et al. 1996; Peebles et al. 2008; Serrador et al. 2000; ter Minassian et al. 1998; Valdueza et al. 1997) . Moreover, studies have shown that the MCA diameter is relatively unchanged in the range of 23-60 mmHg for P a O 2 (Giller et al. 1993; Serrador et al. 2000; Valdueza et al. 1997 ). However, evidence of unchanged MCA diameter during hypoxia is still lacking. Nevertheless, it is noteworthy that the observed MCAv response during isocapnic hypoxia was comparable to findings by Noth et al. (2008) , who have previously assessed the CBF response to isocapnic hypoxia using MRI (Noth et al. 2008) . Importantly, consistent with our observations (Fig. 2) , these authors also reported high intra-subject variability in CBF response to hypoxia (Noth et al. 2008) . Collectively, these findings support the use of MCAv as a valid measure of CBF.
Influence of indomethacin on cerebrovascular reactivity to CO 2 and O 2
Numerous human studies using transcranial Doppler ultrasound (Ivancev et al. 2009; Markus et al. 1994; Xie et al. 2006) , MRI (Bruhn et al. 2001; St Lawrence et al. 2002), 133 Xe method (Jensen et al. 1996) and N 2 O washout method Wennmalm et al. 1983 ) have reported that INDO reduces basal CBF by 25-35% and cerebrovascular CO 2 reactivity by 50-60%. Consistent with these reports, in the present study, INDO reduced resting MCAv by 25% and blunted cerebrovascular CO 2 reactivity by 46% during steady-state hyperoxic hypercapnia (Fig. 1) . In contrast, Pickles et al. (1984) reported a reduced basal CBF without any concurrent changes in cerebrovascular CO 2 reactivity in six participants following 2 days of INDO oral administration (100 mg day -1 ). However, in that study, participants were given 50 mg of INDO the morning of the experiment, whilst the present and other previous studies (Bruhn et al. 2001; Eriksson et al. 1983; Fan et al. 2010; Ivancev et al. 2009; Markus et al. 1994; St Lawrence et al. 2002; Wennmalm et al. 1983; Xie et al. 2006 Xie et al. , 2009 have assessed the effect of INDO on the cerebrovascular CO 2 reactivity following a single larger dose of INDO (100 mg) 90 min prior to measurement. Accordingly, these methodological differences make it difficult to compare the findings of the Pickles et al. (1984) study. Nishimura et al. (1987) have previously found a reduction in the arterial-to-internal venous jugular PCO 2 difference during 5-15 min of hypoxic exposure in healthy humans. From this observation, they concluded that hypoxia-induced increases in CBF would serve to increase the H ? washout from the brain, thereby modulating the ventilatory drive during transient hypoxia. Importantly, these findings highlight the role of cerebrovascular reactivity to hypoxia in the modulation of hypoxic ventilatory response. The effect of INDO on the control of hypoxiainduced vasodilation in the cerebrovasculature has not been examined in humans. Most (Armstead 2000; Coyle et al. 1993 Coyle et al. , 1995 Isozumi et al. 1994; Leffler and Parfenova 1997; Mollace et al. 1997; van Bel et al. 1997 ), but not all (McCalden et al. 1984) , animal studies have reported a reduced cerebrovascular responsiveness to hypoxia with INDO-presumably due to the inhibition of prostaglandin production. Coyle et al. (1993 Coyle et al. ( , 1995 provided evidence to indicate that INDO attenuates hypoxia-induced cerebral vasodilation in a dose-dependent manner. They reported a reduction in CBF with a high dosage of INDO (5 mg kg -1 ) in pigs, whilst no changes were observed with low dosage (0.3 mg kg -1 ). In the present study, INDO (*1.4 mg kg -1 ) did not alter cerebrovascular responsiveness to isocapnic hypoxia (Fig. 2) . Therefore, it seems reasonable to assume that the physiological dosage of INDO used in the present study was insufficient to cause any alterations in the cerebrovascular responsiveness to hypoxia.
Effect of indomethacin on ventilatory sensitivity to CO 2 and O 2 It has been shown in both human Xie et al. 2006 ) and goat (Chapman et al. 1979a ) studies that reductions in both basal CBF and cerebrovascular CO 2 reactivity increase the ventilatory responsiveness to hyperoxic hypercapnia, presumably mediated by reduced H ? ion washout and associated increase in central chemoreceptor activation. In the present study, INDO-induced reduction in cerebrovascular CO 2 reactivity enhanced the ventilatory responsiveness to CO 2 during hyperoxic hypercapnia (Fig. 1) . Importantly, the INDO-induced increase in the ventilatory CO 2 sensitivity in the present study was comparable to those reported by Xie et al. (2006) . Since hyperoxia is known to silence the peripheral chemoreceptor activity in most individuals (Cunningham et al. 1963; Gardner 1980; Mohan and Duffin 1997) , we attributed this increase in _ V E response to hyperoxic hypercapnia associated with INDO to an enhanced central chemoreflex.
An important consideration with regard to the use of INDO to alter ventilatory control is the potential for breathing effects through mechanisms other than at the level of the central chemoreceptors. One hypothesis proposed by Xie et al. (2009) is that INDO may selectively enhance _ V E by enhancing the peripheral chemoreflex (Xie et al. 2009 ). As discussed in the introduction, the role of INDO on the peripheral chemoreflex in humans is unclear. Eur J Appl Physiol (2011) 111:601-610 607 Xie et al. (2006) reported no difference in the _ V E response to CO 2 under the condition of hyperoxia or normoxia following INDO ingestion (100 mg). From this finding, they proposed that INDO does not influence the peripheral chemoreflex in healthy resting humans. Likewise, Chapman et al. (1979a) found, using carotid artery clamping, that the ventilatory response to transient hypoxia is unaltered with moderate reductions in basal CBF (30%) and cerebrovascular CO 2 reactivity in conscious goats. Consistent with these findings, we did not observe any changes in the _ V E response to isocapnic hypoxia with INDOinduced reduction in cerebrovascular CO 2 reactivity (Fig. 2) , thus supporting a preserved peripheral chemoreflex following INDO. Taken together, data from the present study indicate that INDO selectively enhances the central chemoreflex in humans without any concurrent alterations in the peripheral chemoreflex.
Another important consideration is the effect of INDO on cerebral oxygenation. Chapman et al. (1979a) reported a blunted ventilatory response to both hypercapnia and transient hypoxia with severe reductions in CBF (50%), and near abolishment of cerebrovascular CO 2 reactivity blunts the hypoxic ventilatory response. They attributed the latter finding to respiratory neuron depression associated with severe cerebral ischaemia. In the present study, we did not observe a reduction in cerebral oxygenation with INDO administration in healthy adults (Table 1 ). In contrast, previous studies have shown that INDO-induced reduction in basal CBF lowers cellular oxygenation of brain tissues in both preterm infants with ductus arteriosus (Benders et al. 1995; Lemmers et al. 2008; Liem et al. 1994 ) and newborn piglets (Yamashita et al. 1999) . Whilst the discrepancies between these findings are unclear, it is possible that INDO may have differential effect on cerebral oxygenation between adults and preterm infants. Consistent with this suggestion, during conditions of hypotension , exercise (Ainslie et al. 2007 ) and heat stress (Fan et al. 2008) , there have been reports of a maintained cerebral oxygenation despite reductions in MCAv. We acknowledge, however, that since cerebral oxygenation was measured in only seven participants, the effect of INDO on cerebral oxygenation could potentially be masked by insufficient statistical power.
Implications
An observational study by Xie et al. (2005) demonstrated that congestive heart failure patients with central sleep apnoea display a lower cerebrovascular responsiveness to CO 2 compared to patients without central sleep apnoea. Similarly, Reichmuth et al. (2009) found that patients with obstructive sleep apnoea have impaired cerebrovascular function. Recent studies have demonstrated that a single dose of INDO causes breathing instability during wakefulness , increases the risk of central apnoea (Xie et al. 2009 ) and augments obstructive sleep apnoea . The findings from the present study (Fig. 2) indicate that these INDO-induced increases in breathing instability during both wakefulness and sleep are mediated by its influence on the central chemoreceptor activation, rather than any additional changes in the peripheral chemoreflex. Such findings support the role of a blunted cerebrovascular CO 2 reactivity in the pathogenesis of breathing instability.
Conclusion
Together with previous studies (Bruhn et al. 2001; Eriksson et al. 1983; Fan et al. 2010; Ivancev et al. 2009; Kastrup et al. 1999; Markus et al. 1994; St Lawrence et al. 2002; Wennmalm et al. 1983; Xie et al. 2006 Xie et al. , 2009 , data from the present study indicate that a single dose of INDO (100 mg) selectively lowers CBF and blunts the cerebrovascular CO 2 reactivity without any concurrent changes in the cerebrovascular and ventilatory responses to hypoxia in healthy humans.
